COPAD’s Market Debut Tilts Toward Investor Exit as TCV Prepares to Cash Out
Egyptian drugmaker COPAD Pharma is reshaping the blueprint for its planned stock market debut, with the upcoming offering now expected to serve largely as an exit window for existing shareholders rather than a pure capital-raising exercise. At the center of that shift is Tanmiya Capital Ventures (TCV), the private equity investor holding a 21% stake …
COPAD’s Market Debut Tilts Toward Investor Exit as TCV Prepares to Cash Out Read More »











